A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43272 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Carol A Langford und 30 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Abatacept, Granulomatosis with Polyangiitis, Immunosuppressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCRR NIH HHS, NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Objective
To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA).
Methods
In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or equivalent), tapered and discontinued at week 12. Patients already taking methotrexate, azathioprine, mycophenolate, or leflunomide continued this medication at a stable dose. Patients achieving remission remained on their randomized assignment until relapse, early termination, or the common close date 12 months after enrollment of the last patient. Those who had a nonsevere relapse, had nonsevere worsening, or were not in remission by month 6 had the option to receive open‐label abatacept. The primary end point was the rate of treatment failure, defined as relapse, disease worsening, or failure to achieve a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 or 1 by six months.
Results
Sixty‐five patients were randomized; 34 received abatacept and 31 received placebo. No statistical difference in the treatment failure rate was found between those who received abatacept and those who received placebo ( P = 0.853). Treatment with abatacept did not demonstrate any statistical difference from placebo in key secondary end points, including time to full remission (BVAS/WG = 0), duration of glucocorticoid‐free remission, relapse severity, prevention of damage, and patient‐reported quality‐of‐life outcomes. There was no difference in the frequency or severity of adverse events between treatment arms, including infection.
Conclusion
In patients with relapsing, nonsevere GPA, abatacept did not reduce the risk of relapse, severe worsening, or failure to achieve remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic, Cleveland, Ohio.
- St Joseph's Healthcare and McMaster University, Hamilton, Ontario, Canada.
- University of Kansas Medical Center, Kansas City, Kansas.
- Oregon Health and Science University, Portland, Oregon.
- Medius Klinik Kirchheim, Kirchheim unter Teck, and University of Tübingen, Tübingen, Germany.
- Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Carol A Langford, Marcia Friedman, Paul A Monach, Ulrich Specks, Robert Spiera, Elaine Yacyshyn, Rennie L Rhee, David Jayne
Förderung
- NCRR NIH HHS
- NIH HHS
- NIAMS NIH HHS
- Bristol-Myers Squibb
- National Institutes of Health
Zitieren
APA
Langford, C. A., Khalidi, N., Springer, J., Friedman, M., Hellmich, B., Pagnoux, C., Dehghan, N., Gewurz-Singer, O., Koening, C. L., Lin, Y. C., Monach, P. A., Moreland, L. W., Fifi-Mah, A., Flossmann, O., Forbess, L. J., Lanyon, P., Molloy, E., Specks, U., Spiera, R., …, & Vasculitis Clinical Research Consortium and the European Vasculitis Society (2025). A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis. Arthritis & Rheumatology. https://doi.org/10.1002/art.43272
Vancouver
Langford CA, Khalidi N, Springer J, Friedman M, Hellmich B, Pagnoux C, et al. A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 2025. doi:10.1002/art.43272
BibTeX
@article{Langford2025,
author = {Langford, Carol A and Khalidi, Nader and Springer, Jason and Friedman, Marcia and Hellmich, Bernhard and Pagnoux, Christian and Dehghan, Natasha and Gewurz-Singer, Ora and Koening, Curry L and Lin, Yih Chang and Monach, Paul A and Moreland, Larry W and Fifi-Mah, Aurore and Flossmann, Oliver and Forbess, Lindsy J and Lanyon, Peter and Molloy, Eamonn and Specks, Ulrich and Spiera, Robert and Yacyshyn, Elaine and McAlear, Carol A and Burroughs, Cristina and Jones, Rachel B and Rhee, Rennie L and Hajj-Ali, Rula and Warrington, Kenneth J and Cuthbertson, David and Krischer, Jeffrey P and Jayne, David and Merkel, Peter A and Vasculitis Clinical Research Consortium and the European Vasculitis Society, Vasculitis Clinical Research Consortium and the European Vasculitis Society},
title = {A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43272}
}
EUVIMED